Novo Nordisk A/S Sponsored ADR Class BNovo Nordisk A/S Sponsored ADR Class BNovo Nordisk A/S Sponsored ADR Class B

Novo Nordisk A/S Sponsored ADR Class B

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪206.99 B‬USD
3.47USD
‪15.49 B‬USD
‪46.74 B‬USD
‪3.37 B‬
Beta (1Y)
1.30

About Novo Nordisk A/S Class B


CEO
Maziar Mike Doustdar
Headquarters
Bagsværd
Founded
1923
IPO date
May 17, 1974
Identifiers
3
ISIN US6701002056
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS323295972
Novo Nordisk Finance (Netherlands) BV 4.0% 20-NOV-2045
Yield to maturity
4.27%
Maturity date
Nov 20, 2045
N
XS323295590
Novo Nordisk Finance (Netherlands) BV 3.625% 20-FEB-2038
Yield to maturity
3.75%
Maturity date
Feb 20, 2038
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037
Yield to maturity
3.74%
Maturity date
May 27, 2037
N
XS323294453
Novo Nordisk Finance (Netherlands) BV 3.375% 20-FEB-2035
Yield to maturity
3.51%
Maturity date
Feb 20, 2035
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034
Yield to maturity
3.40%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033
Yield to maturity
3.21%
Maturity date
May 27, 2033
N
XS323293716
Novo Nordisk Finance (Netherlands) BV 3.0% 20-FEB-2032
Yield to maturity
3.10%
Maturity date
Feb 20, 2032
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030
Yield to maturity
2.92%
Maturity date
Aug 27, 2030
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031
Yield to maturity
2.91%
Maturity date
Jan 21, 2031
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030
Yield to maturity
2.70%
Maturity date
Mar 31, 2030
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028
Yield to maturity
2.62%
Maturity date
May 27, 2028

See all NVO bonds 

PPH
VanEck Pharmaceutical ETF
Weight
5.26%
Market value
‪62.53 M‬
USD
PVAL
Putnam Focused Large Cap Value ETF
Weight
1.00%
Market value
‪60.23 M‬
USD
AVDE
Avantis International Equity ETF
Weight
0.28%
Market value
‪37.19 M‬
USD
FTHI
First Trust BuyWrite Income ETF
Weight
1.18%
Market value
‪23.59 M‬
USD
PID
Invesco International Dividend Achievers ETF
Weight
2.16%
Market value
‪19.98 M‬
USD
WCMI
First Trust WCM International Equity ETF
Weight
2.00%
Market value
‪18.93 M‬
USD
XMCM
Xtrackers MSCI Emerging Markets Swap UCITS ETF
Weight
1.78%
Market value
‪18.24 M‬
USD
PINK
Simplify Health Care ETF
Weight
5.93%
Market value
‪18.09 M‬
USD
OZEM
Roundhill GLP-1 & Weight Loss ETF
Weight
17.10%
Market value
‪9.56 M‬
USD
AQEC
AQE Core ETF
Weight
1.44%
Market value
‪8.69 M‬
USD

Explore more ETFs